S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
NASDAQ:BLUE

bluebird bio - BLUE Price Target & Analyst Ratings

$6.33
+0.63 (+11.05%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.66
$6.57
50-Day Range
$3.75
$7.31
52-Week Range
$2.87
$25.39
Volume
10.34 million shs
Average Volume
9.07 million shs
Market Capitalization
$488.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

bluebird bio Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$8.50
34.28% Upside
High Prediction$14.00
Average Prediction$8.50
Low Prediction$3.00
TypeCurrent
10/1/21 to 10/1/22
1 Month Ago
9/1/21 to 9/1/22
3 Months Ago
7/3/21 to 7/3/22
1 Year Ago
10/1/20 to 10/1/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
10 Hold rating(s)
16 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.50$9.64$11.75$38.60
Predicted Upside34.28% Upside22.84% Upside14.21% Upside46.10% Upside
Get bluebird bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.


BLUE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BLUE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

bluebird bio Stock vs. The Competition

Typebluebird bioMedical CompaniesS&P 500
Consensus Rating Score
1.91
2.68
2.49
Consensus RatingHoldBuyHold
Predicted Upside34.28% Upside1,099.41% Upside36.03% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1026
73.08%
Underperform Votes
378
26.92%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
852
68.43%
Avg. Underperform Votes
393
31.57%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/20/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$8.00 ➝ $10.00+68.63%
8/19/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell$2.00 ➝ $3.00-48.36%
8/18/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$8.00 ➝ $10.00+47.49%
8/5/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$3.00 ➝ $5.00+5.49%
5/17/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight$3.00-13.29%
5/10/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$10.00 ➝ $8.00+108.33%
4/6/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
3/8/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$12.00 ➝ $8.00+79.78%
11/12/2021Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Zhiqiang Shu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold$11.00-2.83%
11/12/2021BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$21.00 ➝ $13.00+11.30%
11/8/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Sector Perform$26.00 ➝ $14.00+12.27%
9/22/2021Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Difei Yang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$29.00 ➝ $23.00+27.85%
8/10/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
8/10/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Gerberry
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$41.00 ➝ $22.00+14.70%
8/9/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$31.00 ➝ $18.00-0.88%
6/15/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
3/29/2021Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$30.00 ➝ $35.00+10.13%
3/29/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
2/17/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$76.00 ➝ $39.00+37.13%
12/9/2020Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/3/2020Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$86.00 ➝ $100.00+25.49%
(Data available from 10/1/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BLUE Price Target - Frequently Asked Questions

What is bluebird bio's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for bluebird bio stock is Hold based on the current 2 sell ratings, 8 hold ratings and 1 buy rating for BLUE. The average twelve-month price prediction for bluebird bio is $8.50 with a high price target of $14.00 and a low price target of $3.00. Learn more on BLUE's analyst rating history.

Do Wall Street analysts like bluebird bio more than its competitors?

Analysts like bluebird bio less than other Medical companies. The consensus rating for bluebird bio is Hold while the average consensus rating for medical companies is Buy. Learn more on how BLUE compares to other companies.

Do MarketBeat users like bluebird bio more than its competitors?

MarketBeat users like bluebird bio more than other Medical companies. 73.08% of MarketBeat users gave bluebird bio an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Is bluebird bio being upgraded by Wall Street analysts?

Over the previous 90 days, bluebird bio's stock had 2 upgrades by analysts.

Does bluebird bio's stock price have much upside?

According to analysts, bluebird bio's stock has a predicted upside of 20.60% based on their 12-month price targets.

What analysts cover bluebird bio?

bluebird bio has been rated by Barclays, Raymond James, SVB Leerink, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:BLUE) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.